Laura Ann Mcallister

US Patent:

20120302599, Nov 29, 2012

Filed:

Nov 30, 2011

Appl. No.:

13/307636

Inventors:

Amy B. Dounay - Ledyard CT, US
Laura McAllister - Pawcatuck CT, US
Vinod D. Parikh - Mystic CT, US
Suobao Rong - Groton CT, US
Patrick R. Verhoest - Old Lyme CT, US

International Classification:

A61K 31/437
A61P 25/00
A61P 9/10
A61P 9/04
A61P 25/28
A61P 21/02
A61P 25/08
A61P 25/06
A61P 13/02
A61P 25/30
A61P 25/16
A61P 27/02
A61P 25/18
A61P 25/24
A61P 25/22
A61P 31/00
A61P 37/00
A61P 1/16
A61P 35/00
A61P 27/16
A61P 1/08
A61P 25/14
C07D 471/04

US Classification:

514303, 546119

Abstract:

Compounds of Formula I:wherein X, Y, Z, R, R, R, Rare as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

US Patent:

20140057938, Feb 27, 2014

Filed:

Oct 31, 2013

Appl. No.:

14/068707

Inventors:

LAURA ANN MCALLISTER - ARLINGTON MA, US
VINOD DIPAK PARIKH - MYSTIC CT, US
SUOBAO RONG - DOYLESTOWN PA, US
PATRICK ROBERT VERHOEST - NEWTON MA, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 471/04

US Classification:

514303, 546119

Abstract:

Compounds of Formula I:wherein X, Y, Z, R, R, R, Rare as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

US Patent:

20210309659, Oct 7, 2021

Filed:

Jun 1, 2021

Appl. No.:

17/335666

Inventors:

- New York NY, US
Christopher Ryan Butler - Canton MA, US
Elizabeth Mary Beck - Oxford, GB
Michael Aaron Brodney - Newton MA, US
Matthew Frank Brown - Stonington CT, US
Laura Ann McAllister - Arlington MA, US
Erik Alphie LaChapelle - Uncasville CT, US
Adam Matthew Gilbert - Guilford CT, US

International Classification:

C07D 471/04
A61P 25/00
A61P 25/16
A61P 25/18
A61P 25/28
A61K 31/437

Abstract:

The present invention provides, in part, compounds of Formula I:or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R, R, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

US Patent:

20210309669, Oct 7, 2021

Filed:

Jul 10, 2019

Appl. No.:

17/260247

Inventors:

- New York NY, US
Christopher Ryan Butler - Canton MA, US
Laura Ann McAllister - Arlington MA, US
Steven Victor O'Neil - East Lyme CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 491/107

Abstract:

The present invention provides, in part, a compound selected from the group consisting of:

US Patent:

20210024497, Jan 28, 2021

Filed:

Mar 25, 2019

Appl. No.:

17/040479

Inventors:

- New York NY, US
Erik Alphie LaChapelle - Uncasville CT, US
Christopher Ryan Butler - Canton MA, US
Natasha Mariam Kablaoui - Newton MA, US
Michael Aaron Brodney - Newton MA, US
Laura Ann McAllister - Arlington MA, US
Qingyi Yang - Lexington MA, US
Christopher John Helal - Mystic CT, US
Damien Webb - Bottminggen, CH

International Classification:

C07D 401/14
C07D 401/12
C07D 417/14
C07D 471/04
C07D 491/107
C07D 413/14

Abstract:

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

US Patent:

20200262833, Aug 20, 2020

Filed:

Jun 14, 2018

Appl. No.:

16/625202

Inventors:

- New York NY, US
Michael Aaron Brodney - Newton MA, US
Matthew Frank Brown - Stonington CT, US
Christopher Ryan Butler - Canton MA, US
Adam Matthew Gilbert - Guilford CT, US
Erik Alphie Lachapelle - Uncasville CT, US
Laura Ann McAllister - Arlington MA, US
Daniel Paul Uccello - Colchester CT, US
Lei Zhang - Auburndale MA, US

International Classification:

C07D 471/04
A61P 25/28
A61P 25/30
A61P 25/18

Abstract:

The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R)a, (R)b, (R)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

US Patent:

20200207762, Jul 2, 2020

Filed:

Feb 21, 2020

Appl. No.:

16/797966

Inventors:

- New York NY, US
Christopher Ryan Butler - Canton MA, US
Elizabeth Mary Beck - Oxford, GB
Michael Aaron Brodney - Newton MA, US
Matthew Frank Brown - Stonington CT, US
Laura Ann McAllister - Arlington MA, US
Erik Alphie LaChapelle - Uncasville CT, US
Adam Matthew Gilbert - Guilford CT, US

International Classification:

C07D 471/04
A61P 25/28
A61P 25/18
A61P 25/16
A61P 25/00

Abstract:

The present invention provides, in part, compounds of Formula I:or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R, R, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

US Patent:

20190382359, Dec 19, 2019

Filed:

Aug 21, 2019

Appl. No.:

16/547037

Inventors:

- NEW YORK NY, US
LAURA ANN MCALLISTER - ARLINGTON MA, US
ELIZABETH MARY BECK - ABINGDON, GB
MICHAEL AARON BRODNEY - NEWTON MA, US
ADAM MATTHEW GILBERT - GUILFORD CT, US
CHRISTOPHER JOHN HELAL - MYSTIC CT, US
DOUGLAS SCOTT JOHNSON - CONCORD MA, US
JUSTIN IAN MONTGOMERY - LEDYARD CT, US
STEVEN VICTOR O'NEIL - EAST LYME CT, US
BRUCE NELSEN ROGERS - BELMONT MA, US
PATRICK ROBERT VERHOEST - NEWTON MA, US
DAMIEN WEBB - BROOKLINE MA, US

Assignee:

PFIZER INC. - NEW YORK NY

International Classification:

C07D 295/14
C07D 493/10
C07D 405/12
C07D 413/14
C07D 405/14
C07F 9/6561
C07D 515/10
C07D 471/08
C07D 211/48
C07D 487/04
C07D 471/10
C07D 401/12
C07D 491/107
C07D 498/10
C07D 403/04
C07D 401/04
C07D 401/14

Abstract:

The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Author:

Laura McAllister

ISBN #:

0708318959